  
 
Study Title:  A Phase 1B/[ADDRESS_402265] Disease  
Protocol Number:  EQ001- aGVHD- [ADDRESS_402266](s):  EQ001 
 
Sponsor:  Equillium, Inc.  
 
Development Phase:  Phase 1b/[ADDRESS_402267] Number:  NCT 03763318 
 
Document Version Date:   [ADDRESS_402268]/Independent  
Ethic s Committee, or as required by [CONTACT_2371]. Persons to whom this information is disclosed should be informed that this information 
is confidential and may not be further disclosed without the express permission of Equillium AUS Pty Ltd . 
Confidentiality Statement  
Information contained in this protocol is proprietary and confidential in nature and may not be used, 
divulged, published, or otherwise disclosed to others except to the extent necessary to obtain approval of the 
Institutional Review Board or as required b y law. Persons to whom this information is disclosed should be 
informed that this information is confidential and may not be further disclosed without the express permission 
of Equillium, Inc.  
  
A PHASE  1B/[ADDRESS_402269]  DISEASE  
CLINICAL STUDY  PROTOCOL : EQ001 -aGVHD -001 
IND Number:  139877  
Indication:  Acute Graft Versus Host Disease  
Sponsor:  Equillium Inc.  
 
 
 
  
   
 
  
  
  
  
  
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  2 of 87 
Equillium, Inc.  Confidential  SPONSOR SIGNATURE [CONTACT_1783]  
A PHASE 1b/[ADDRESS_402270]  DISEASE  

Protocol: EQ001 -aGVHD -001 
 Page  3 of 87 
Equillium, Inc.  Confidential   
 
 
 
 
 
  
 
 
 
  
 
 
  
 
  
 
 
 
  
 
 
  
 
  
 
 
  
 
  
 
 
 
 
 
 
   
   
   
   

Protocol: EQ001 -aGVHD -001 
 Page  4 of 87 
Equillium, Inc.  Confidential  SYNOPSIS  
Name [CONTACT_73988]:  Equillium , Inc. 
Name [CONTACT_2756]: EQ001  Name [CONTACT_3261]: Itolizumab (Bmab 600)  
Title of Study:  
A Phase 1b/[ADDRESS_402271] Disease  
Study Centers:  
Approximately 20 sites in North America . Additional sites and/or countries may be added, depending on subject 
accrual rates.  
Study Period:  
Approximately 12 months (2 months of treatment, 10 months 
follow -up, total of 12 months on study) for Part A and Part B  Phase of Development:  
Phase 1b – Study P art A 
Phase 2 – Study P art B 
Objectives:  
The objectives of Part A of the  study are to:  
Primary  
• Determine the safety and tolerability of intravenous (IV) dosing of EQ001 in subjects with newly 
diagnosed acute graft versus host disease (aGVHD)  
• Determine optimal IV dose level(s) of EQ001 in subjects with newly diagnosed aGVHD  
Secondary  
• To characterize the pharmacokinetics (PK) of EQ001 in subjects with newly diagnosed aGVHD  
•  
  
• To assess the clinical activity of EQ001 in subjects with newly diagnosed aGVHD  
The objectives of P art B of the study are to:  
Primary  
• To define the clinical activity of EQ001 in subjects with newly diagnosed aGVHD  
Secondary  
• To further characterize the s afety, tolerability,  in subjects with newly diagnosed aGVHD  
Study Design:  
This is a multi -center study to evaluate the safety, tolerability, PK, , and clinical activity of EQ001 in subjects 
with an initial clinical presentation of aGVHD.  The study will enroll up to approximately 100 subjects in two (2) parts: 
• Part A – Open-label, cohort based, dose escalation component : 
Part A will enroll approxim ately  [ADDRESS_402272] more  data. 
• Part B – Randomized, double -blind, placebo -controlled  component : 
Part B will enroll approximately  60 additional subjects, randomized in a 2:1 ratio to either active treatment 
with an optimally defined dose of EQ001 (40) or placebo (20), to determine the safety, tolerability, and 
clinical activity of EQ00 1. 

Protocol: EQ001 -aGVHD -[ADDRESS_402273] treatment for aGVHD with 
systemic ally administered  corticosteroids , prednisone at approximately 1 -2 mg/kg/day (or its equivalent)  at the 
time of the first dose of study drug administration .  The first dose of study drug must be administered within 
72 hours (3 days) of receipt of the  subject’s  initial  corticosteroid dos e. 
Screening assessments will include: a medical history , physical exam , aGVHD organ stag es and overall clinical 
grading  aGVHD activity index [aGVHD -AI] , vital signs, an electrocardiogram  
(ECG), laboratory tests (clinical chemistries, hematology , coagulation pane l, urinalysis , pregnancy test in  females 
of childbearing potential only  and viral serologies ), study eligibility check , recording of prior and concomitant 
medications and treatment s and collection of relevant biopsy data . 
During the study , subjects will undergo periodic evaluations including physical exam s, aGVHD organ s tages  and 
overall clinical grading  aGVHD -AI  vital signs, ECG, laboratory tests , PK (Part  A 
only)/  and anti-drug antibody ( ADA ) sampling,  a skin biopsy (optional in Part B only), stool sample 
(optional in Part B only), recording of concomitant medication usage, adverse event (AE) monitoring , disease  
progression  assessment s and collection of relevant biopsy data . 
Part A of the study will util ize a standard 3  + 3 dose escalation design  until a dose is selected .  Cohort enrollment 
will proceed in a sequential manner to evaluate escalating dose levels of EQ001: Cohort  1 – 0.4 mg/kg, Cohort  2 – 
0.8 mg/kg,  Cohort  3 – 1.6 mg/kg , and Cohort 4 – 2.4 m g/kg.   Dose escalation will proceed if no predefined 
stoppi[INVESTIGATOR_23893].  The dose -limiting toxicity (DLT) assessment period will be the first 29  days of 
treatment (i.e.,  Study Days  1 to 29) and will guide dose escalation decisions.  Subjects will b e considered 
evaluable for DLT assessment if they have received at least two doses of study drug and completed study 
assessments through Study Day [ADDRESS_402274] 29 
days on study.  Enrollment of the next higher dose cohort will not commence until all safety data from all subjects 
from prior cohorts and  all available safety data from  the current cohort through Study Day  29 are reviewed by [CONTACT_325695] (D SMC) and approval is granted for dose escalation.   
 
 
 
Part B of the study will be randomized,  double blinded, and placebo controlled, and will commence following  the 
completion of Part A  and approval by [CONTACT_941] D SMC.  In P art B, up to 60  subjects will be enrolled to better define the 
safety, tolerabilit y, , and immunogenicity  of EQ001 , and to explore the clinical activity of EQ001 
in subjects with newly diagnosed  aGVHD . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  6 of 87 
Equillium, Inc.  Confidential   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  8 of 87 
Equillium, Inc.  Confidential  experiences a DLT, then 3  additional subjects will be enrolled at the same dose level for a total of up to 
6 evaluable subjects.  If 1 out of the 6  subjects experience a DLT, then escalation may proceed to the nex t higher 
dose level.  If two ( 2) or more subjects experience a DLT, no additional subjects will be enrolled in the cohort, and 
the next lower dose level will enroll additional subjects for a total of 6  evaluable subjects.  
AEs will be graded by [CONTACT_325696] (CTCAE) 
v5.0.  Further, the relationship of each AE to the study drug will be assessed by [CONTACT_325697], 
probably related, possibly related, unlikely related , or not related.   
 
 
  
  
Subject Stoppi[INVESTIGATOR_2121]:  
Dosing of EQ001 will be permanently discontinued in a subject if any of the following occu rs: 
During Part A:  
• Any DLT  
  
 
  
During Part B:  
• Study drug related toxicity that cannot be controlled  with supportive care despi[INVESTIGATOR_040] 1 dose reduction and/or delay 
of treatment for up to 1 week  
  
 
  
During any part of the study:  
• Withdrawn consent  
• Investigator or Sponsor c onsiders that the subject will not benefit from further investigational product  
• Pregnancy  
• Subject is not able to comply with the study requirements  
• Sponsor terminates the study  
• A regulatory authority mandates study  dosing cessation  
Number of Subjects  Planned:  
Up to a pproximately 100 subjects  with newly diagnosed  aGVHD are planned to be enrolled in the study.  
Diagnosis and Main Criteria for Inclusion:  
Inclusion Criteria : 
Subject s must meet all the following inclusion criteria to be eligible for study participation:  
1. Male or female subject at least  [ADDRESS_402275] allogeneic hematopoietic stem cell transplantation (allo HSCT) using myeloablative or 
non-myeloablative conditioning regimen s. 
  
 
 

Protocol: EQ001 -aGVHD -[ADDRESS_402276]’s enrollment . 
Exclusion Criteria : 
Subject s meeting any of the following exclusion criteria are not eligible for study participation:  
1. Presence of morphologic relapsed primary malignancy, treat ment  for relapse after alloHSCT was performed, 
or require ment for  rapid immunosuppressive treatment withdrawal for early malignancy relapse . 
2. Evidence of graft failure  based on c ytopenia (s), as determined by [CONTACT_093] . 
3. Evidence of post -transplant lymphoproliferative disease.  
  
 
  
 
  
  
 
 
 
  
  
   
 

Protocol: EQ001 -aGVHD -[ADDRESS_402277] ’s physical examination findings, vital signs, and ECG 
findings.  
 
 
A detailed description of data analysis and statistical methods to be used will be outlined separately in a Statistical 
Analysis Plan  (SAP) . 
  

Protocol: EQ001 -aGVHD -[ADDRESS_402278] an ................................ ................................ ................. 28 
3.2. Data and Safety Monitoring Committee (DSMC), Dose -Limiting Toxicity, 
and Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ [ADDRESS_402279] Stoppi[INVESTIGATOR_2121]  ................................ ................................ ............ 31 

Protocol: EQ001 -aGVHD -001 
 Page  14 of 87 
Equillium, Inc.  Confidential  3.2.3.  Study Stoppi[INVESTIGATOR_007] C riteria  ................................ ................................ ............... 32 
3.3. Rationale for Study Design  ................................ ................................ ....................... 32 
3.4. Study Duration and Number of Centers  ................................ ................................ ...33 
4. STUDY POPULATION SELECTION  ................................ ................................ ................ 34 
4.1. Study Population  ................................ ................................ ................................ .......34 
  
4.3. Inclusion Criteria  ................................ ................................ ................................ ......34 
4.4. Exclusion Criteria  ................................ ................................ ................................ .....35 
5. STUDY TREATMENT(S)  ................................ ................................ ................................ ..37 
  
5.2. Study Drug  ................................ ................................ ................................ ................ 37 
5.3. Treatment(s) Administered  ................................ ................................ ....................... 38 
5.3.1.  Part A ................................ ................................ ................................ ........... 38 
5.3.2.  Part B ................................ ................................ ................................ ........... 38 
  
  
5.4. Prior and Concomitant Medication  ................................ ................................ ........... 40 
5.4.1.  Permitted Therapi[INVESTIGATOR_014]  ................................ ................................ ..................... 40 
5.4.2.  Prohibited Therapi[INVESTIGATOR_014] ................................ ................................ .................... 41 
5.5. Treatment Compliance  ................................ ................................ .............................. 41 
  
5.7. Enrollment or Randomization and Blinding  ................................ ............................. 41 
5.7.1.  Part A  ................................ ................................ ................................ ........... 41 
5.7.2.  Part B  ................................ ................................ ................................ ........... 42 
  
6. STUDY PROCEDURES  ................................ ................................ ................................ ......44 
6.1. Screening and Informed Consent  ................................ ................................ .............. 44 
6.2. Demographics and Medical History  ................................ ................................ ......... 44 
6.3. Physical Exam ................................ ................................ ................................ ........... 45 
6.4. Vital Signs ................................ ................................ ................................ ................. 45 
6.5. Disease Progression Assessment  ................................ ................................ .............. 45 

Protocol: EQ001 -aGVHD -001 
 Page  15 of 87 
Equillium, Inc.  Confidential  6.6. aGVHD Organ Stages, Overall aGVHD Clinical Grades, aGVHD Activity 
Index Scoring Algorithm, and Ann Arbor Risk Score ................................ .............. 46 
6.7. Biopsy Review  ................................ ................................ ................................ .......... 46 
6.8. Minimal Residual Disease (MRD)  ................................ ................................ ........... 46 
6.9. Chronic GVHD (cGVHD)  ................................ ................................ ........................ 46 
6.10.  12-Lead Electrocardiography  ................................ ................................ ................... 46 
6.11.  Clinical Laborator y Tests ................................ ................................ .......................... 47 
6.11.1.  Local Laboratory Parameters  ................................ ................................ ......47 
6.11.2.  Central Laboratory Parameters  ................................ ................................ ....48 
[IP_ADDRESS].  Pharmacokinetic (Part A only)  ................................ .................. 48 
[IP_ADDRESS].  Anti-Drug Antibody (ADA) and Neutralizing ADA (NAB)  ....48 
  
  
  
6.11.3.  Priority for Laborator y Sample Collection  ................................ .................. 51 
6.11.4.  Research Use of Stored Human Samples , Specimens, or Data  ................... 51 
6.12.  Removal of Subjects from the Study  ................................ ................................ ........ 51 
7. ADVERSE EVENTS  ................................ ................................ ................................ ........... 52 
7.1. Severity  ................................ ................................ ................................ ..................... 52 
7.2. Relationship  ................................ ................................ ................................ .............. 53 
7.3. Clinical Laboratory Adverse Events  ................................ ................................ ......... 53 
7.4. Serious Adverse Events  ................................ ................................ ............................ 54 
7.5. Reporting Adverse Events  ................................ ................................ ........................ 54 
7.5.1.  Reporting Procedures for Non -Serious Adverse Events  ............................. 54 
7.5.2.  Reporting Procedures Serious Adverse Events  ................................ ........... 55 
  
7.7. Expected Clinical Adverse Events in Subjects with aGVHD ................................ ...56 
  
  
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  16 of 87 
Equillium, Inc.  Confidential    
  
  
  
  
  
 
  
  
  
  
  
9. PLANNED STATISTICAL METHODS  ................................ ................................ ............. 66 
9.1. General Considerations  ................................ ................................ ............................. 66 
  
9.3. Analysis Population s................................ ................................ ................................ .66 
9.3.1.  Safety Population  ................................ ................................ ........................ 66 
9.3.2.  Pharmacokinetic Analysis Population (Part  A) ................................ ........... 66 
  
9.3.4.  Efficacy Population (Part  B) ................................ ................................ .......[ADDRESS_402280] (IRB) Approval  ................................ ............................. [ADDRESS_402281] Informat ion and Consent  ................................ ................................ ............. 70 

Protocol: EQ001 -aGVHD -001 
 Page  17 of 87 
Equillium, Inc.  Confidential  10.5.  Confidentiality  ................................ ................................ ................................ .......... 71 
10.6.  Study Initiation  ................................ ................................ ................................ ......... 72 
10.7.  Case Report Forms and Study Records  ................................ ................................ ....72 
10.8.  Study Moni toring  ................................ ................................ ................................ ......73 
10.9.  Access to Source Documentation  ................................ ................................ ............. 73 
10.10.  Study or Study Site Termination  ................................ ................................ .............. 73 
 
 
10.13.  Quality Assurance  ................................ ................................ ................................ .....74 
10.14.  Retention of Data  ................................ ................................ ................................ ......75 
10.15.  Study Report and Publications  ................................ ................................ .................. 75 
  
  
 
  
  
  
  
  
  
 
 
 
 
 
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  18 of 87 
Equillium, Inc.  Confidential    
  
  
  

Protocol: EQ001 -aGVHD -[ADDRESS_402282]  allogeneic hematopoietic stem cell transplantation  
ALT  alanine amin otransferase (SGPT)  
ANC  absolute neutrophil count  
aPTT  activated partial thromboplastin time  
AST  aspartate aminotransferase (SGOT)  
AUC  area under the time -concentration curve  
BUN  blood urea nitrogen  
CFR  Code of Federal Regulations  
cGVHD  chronic graft versus host disease  
Cl Clearance  
Cmax maximum serum drug concentration  
Cmin minimum serum drug concentration  
CMV  Cytomegalovirus  
CRF  case report form  
CSR  clinical study report  
CTCAE  Common Terminology Criteria for Adverse Events  
DLI donor lymphocyte infusion  
DLT  dose-limiting toxicity  
DNA  deoxyribonucleic acid  
DSMC  Data and Safety Monitoring Committee  
EBV  Epstein Barr virus  
ECG  Electrocardiogram  
eCRF  electronic case report form  
EOI end of infusion  
ET early termination  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GGT  gamma glutamyl transferase  
GI Gastrointestinal  
GVHD  graft versus host disease  
HBV  hepatitis B virus  
Hct Hematocrit  
HCV  hepatitis C virus  
Hgb Hemoglobin  
HHV -[ADDRESS_402283]  

Protocol: EQ001 -aGVHD -[ADDRESS_402284]  hematopoietic stem cell transplantation  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council  on Harmonisation  
IgG1  immunoglobulin G1  
IND Investigational New Drug  
INR International Normalized Ratio  
  
IRB Institutional Review Board  
IV Intravenous  
IWRS interactive web response  system  
LDH  lactic dehydrogenase  
LYO  Lyophilization  
mAb  monoclonal antibody  
MAGIC  Mount Sinai Acute GVHD International Consor tium 
MedDRA  Medical Dictionary for Regulatory Activities  
NAB  neutralizing  ADA  
NYHA  [LOCATION_001] Heart Association  
PBMC  peripheral blood mononuclear cell  
  
Ph.Eur.  European Pharmacopoeia  
PK Pharmacokinetics  
PT preferred term  
RBC  red blood cells  
RNA  ribonucleic acid  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SC Subcutaneous  
Sc scavenger receptor cysteine -rich 
SCID  severe combined immune deficiency  
SGOT  serum glutamic oxaloacetic transaminase (AST)  
SGPT  serum glutamic pyruvic transaminase (ALT)  
SOC  system organ class  
t½ half-life 
TCR  T cell receptor  
TEAEs  treatment -emergent adverse events  
TESAEs  treatment -emergent serious adverse events  
Th17  T helper [ADDRESS_402285]  upper limit of normal  
USP [LOCATION_002] Pharmacopeia  
US [LOCATION_002]  
Vd volume of distribution  
WBC  white blood cell (count)  

Protocol: EQ001 -aGVHD -001 
 Page  22 of 87 
Equillium, Inc.  Confidential   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  23 of 87 
Equillium, Inc.  Confidential    
  
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  24 of 87 
Equillium, Inc.  Confidential    
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -[ADDRESS_402286] recipi[INVESTIGATOR_840].  

Protocol: EQ001 -aGVHD -[ADDRESS_402287] body of clinical data exists to inform the selection of a starting dose, and dose regimen , 
for EQ001 in this study.  
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  27 of 87 
Equillium, Inc.  Confidential  2. STUDY  OBJEC TIVES  
2.1. Study P art A 
2.1.1.  Primary Objectives  
The primary objectives  of Part A of this study are:  
• Determine the safety and tolerability of intravenous (IV) dosing of EQ001 in subjects with 
newly diagnosed acute graft versus host disease (aGVHD)  
• Determine optimal I V dose level(s) of EQ001 in subjects with newly diagnosed aGVHD  
2.1.2.  Secondary Objectives  
The secondary objectives of Part A of this study are  as follows : 
• To characterize the pharmacokinetics (PK) of EQ001 in subjects with newly diagnosed 
aGVHD  
  
 
  
• To asses s the clinical activity of EQ001 in subjects with newly diagnosed aGVHD  
2.2. Study P art B 
2.2.1.  Primary Objective  
The primary objective of P art B of this study is to define the clinical activity of EQ001 in 
subjects with newly diagnosed aGVHD . 
2.2.2.  Secondary Objective  
The secondary objective of P art B of this study is to further characterize the safety, tolerability, 
 of EQ001 in subjects with newly diagnosed aGVHD . 

Protocol: EQ001 -aGVHD -001 
 Page  28 of 87 
Equillium, Inc.  Confidential  3. INVESTIGATIONAL PLAN  
3.1. Overall Study Design and Plan  
This is a multi -center study to evaluate the safety, tolerability, PK, and clinical activity of 
EQ001 in subjects with an initial clinical presentation of aGVHD.  The study will enroll up to 
approximately  100 subjects in two (2)  parts  
• Part A – Open -label, cohort based, dose escalation component : 
Part A will enroll approximately  [ADDRESS_402288] more  data. 
• Part B – Randomized, double -blind, placebo -controlled component : 
Part B will enroll approximately  60 additional subjects, randomized in a 2:1 ratio to either 
active treatment with an optimally defined dose of EQ001 (40) or placebo (20), to determine 
the safety, tolerability, and clinical activity of EQ001 .  
Part A of the study will utilize a standard 3 + 3 dose escalation design  until a dose is selected .  
Cohort enrollment will proceed in a sequential manner to evaluate the escalating dose levels of 
EQ001 ( Section  5.3.1 ).  Dose escalation will proceed as long as no predefined stoppi[INVESTIGATOR_325683].  The dose -limiting toxicity (DLT ) assessment period will be the first 29  days of 
treatment (i.e., Study Days 1 to 29) and will guide dose escalation decisions.  Subjects will be 
considered evaluable for DLT assessment if they have received at least two doses of study drug 
and completed t hrough Study Day [ADDRESS_402289] 29  days on study.  Enrollment of the next higher dose cohort will not commence 
until all safety data from all subjects from prior cohorts and all available safet y data from the 
current cohort through Study Day 29 are reviewed by [CONTACT_140308] 
(DSMC) and approval is granted for dose escalation.  An o ptimal  dose of EQ001 will be 
determined based on all available data, including safety,  tolerability, . 
Once a dose is selected,  up to approximately  [ADDRESS_402290] dose of study drug within 
72 hours (3 days) of the subject’s initial sy stemically administered corticosteroid dose.  

Protocol: EQ001 -aGVHD -001 
 Page  29 of 87 
Equillium, Inc.  Confidential  The systemically administered corticosteroid treatment will be prednisone, at approximately 1 -
2 mg/kg/day  (or its equivalent)  at the time of first dose of study drug administration ; however, the 
investigator can adjust dosing as clinically indicated during the study  according to the 
recommended treatment and tapering schedule  
Subjects in Parts  A and B will have the same study assessments except as noted.  All subjects 
will have two (2)  months of dosing compris ing five (5) doses of study drug, administered IV 
every fourteen (14) days, and ten (10) months of fo llow up for a total of twelve (12) months in 
the study . The follow -up period will consist of a 2 -month Safety Follow -Up period (through Day 
169) and then an 8 -month Long -Term Follow -Up period (through Day 337).   
 overview of the study timeline for Part A and Part B, respectively.  During the  
Long -Term Follow -Up period , the site will phone subjects on Study Days [ADDRESS_402291] 
information on  disease status (disease relapse or cGVHD), long-term survival , and safety  (eg, 
recent hospi[INVESTIGATOR_325684] s). 

Protocol: EQ001 -aGVHD -001 
 Page  30 of 87 
Equillium, Inc.  Confidential  3.2. Data and Safety Monitoring Committee (DSMC), Dose -Limiting Toxicity, and 
Stoppi[INVESTIGATOR_325685].  An independent DSMC will be established to review clinical trial data prior to dos e 
escalation and during Part B on an as -needed basis.  A statistician, serving as a non -voting 
member to the DSMC, will provide data preparation support to the DSMC.  A sponsor representative  
will also serve as a non -voting member of the DSMC to facilitate  sponsor internal planning.  
The Chair of the DSMC will be informed by [CONTACT_325698].  A formal DSMC Charter will be 
prepared and finalized prior to study enroll ment.  
The DSMC will review all available clinical and laboratory safety data at defined intervals 
during the conduct of each cohort in Part  A and periodically during Part  B of the study.  Based 
on a review of available data, the DSMC will make recommendati ons regarding the continuation, 
discontinuation or modification of the study, cohort advancement (during Part  A), and 
progression to Part  B of the study.  
During Part  A of the study, the DSMC will apply the following dose -escalation rules per cohort.  
• For ea ch cohort, if 0  of the 3  initial evaluable subjects experiences a DLT (see  
Section  3.2.1  for DLT definition), then escalation may occur to the next higher dose level.  
• If 1 of the 3  initial subjects experiences a DLT, then 3  additional subjects will be enrolled at 
the same dose le vel for a total of up to 6  evaluable subjects.  
• If 1 out of the 6  subjects experience a DLT, then escalation may proceed to the next higher 
dose level.  
• If two  (2) or more subjects experience a DLT, no additional subjects will be enrolled in the 
cohort, and the next lower dose level will enroll additional subjects for a total of 6  evaluable 
subjects.  

Protocol: EQ001 -aGVHD -001 
 Page  31 of 87 
Equillium, Inc.  Confidential  The Sponsor  will apply the following criteria to the determination of optimal dose in Part A of 
the study:  
• Adequate safety without DLT  
and 
  
If more than one dose meets these criteria, then additional safety, tolerability, PK,  and 
efficacy data will be taken into consideration to select a dose.  
DSMC decisions regarding advancement to the next higher cohort will be governed by [CONTACT_325699] a maximally tolerated dose (MTD).  As such, no 
further dose escalations will occur once the second of two administered dose levels meet the 
criteria for an optimal dose, even if the observed safety and tole rability profile of the second 
(higher) dose level supports further dose escalation.  
Additional subjects may be enrolled in cohorts  if approved  by [CONTACT_941] D SMC  to further characterize 
drug safety, tolerability, or efficacy.  Also, the DSM C may recommend modification of the doses 
to be evaluated, to not initiate specific dose cohorts, to initiation additional dose cohorts, or to 
terminate the study if it is deeme d necessary.  Appropriate regulatory approvals will be obtained 
prior to initiation of any recommended changes by [CONTACT_6802], as required.  
3.2.1.  Dose -Limiting Toxicities  
During the 3+[ADDRESS_402292] possibly related to the study drug are considered DLTs during the DLT 
window Study Days 1 –29: 
   
   
3.2.2.  Subject Stoppi[INVESTIGATOR_325686]001 will be permanently discontinued in a subject if any of the following occur:  
During Part A:  
• Any DLT  
  
 
  
During Part B:  
• Study drug related toxicity that cannot be controlled with support ive care, despi[INVESTIGATOR_040] 1  dose 
reduction and/or delay of treatment for up to 1 week  

Protocol: EQ001 -aGVHD -001 
 Page  32 of 87 
Equillium, Inc.  Confidential    
 
 
During any part of the study:  
• Withdrawn consent  
• Investigator or Sponsor considers that the subject will not benefit from further investigational 
product  
• Pregnancy  
• Subject is not able to comply with the study requirements  
• Sponsor terminates the study  
• A regulatory authority mandates study dosing cessation  
The investigator will classify AEs that are observed in a subject as either expected to occur based 
on the underlying dise ase (Section  7.7) and/or are consistent with the AE profile in the current 
EQ001  Investigator’s  Brochure , or unexpected based on their prior clinical experience and 
management of aGVHD patients.  
3.2.3.  Study Stoppi[INVESTIGATOR_325687].   
 
 
  
 
 
If the recommendation of the DSMC is to halt st udy dosing for all subjects or pause enrollment, 
it can be resumed based on the recommendation of the DSMC after further review of all 
available safety data and notifications of/submission to appropriate regulatory agencies and 
institutional review committ ees, in line with country -specific regulations.  
3.3. Rationale for Study Design  
The design of this study includes both an open -label (Part A) as well as a double -blinded and 
placebo -controlled (Part B) component.  A two -part study utilizing different designs wa s chosen 
to support the attainment of the objectives that are specific to each part of the study.  
Part A has been designed to explore the safety and tolerability of ascending dose levels of the IV 
administration of multiple doses of EQ001.  An open -label d esign is supported by [CONTACT_325700] -label  safety 
data generated in this study.  A cohort -based dose escalation design was chosen to rigorously 
evaluate, and conservati vely escalate, IV doses of EQ001.  Once a  dose is selected  in Part A , up 
to 15 additional subjects will be enrolled at that dose level for additional data.  

Protocol: EQ001 -aGVHD -[ADDRESS_402293] 2  months of treatment and 10  months of follow -up (2 months of s afety 
follow -up and 8 months of long -term follow -up), for a total of 12  months on study.  
This study will be conducted at approximately 20 clinical sites in North America .  Additional 
sites and/or countries m ay be added, depending o n subject accrual rates.  

Protocol: EQ001 -aGVHD -[ADDRESS_402294] s meeting any of the following exclusion criteria are not eligible for study participation:  
1. Presence of morphologic relapsed primary malignancy, treat ment  for relapse after 
alloHSCT was performed, or requirement for rapid immunosuppressive treatment 
withdrawal for early malignancy relapse.  
2. Evidence of graft failure  based on cytopenia (s), and as determined by [CONTACT_093] . 
3. Evidence of post -transplant lymphoproliferative di sease  
  
 
  
 
  
  
 
 
 
  
  
   
  
 
  

Protocol: EQ001 -aGVHD -[ADDRESS_402295]: the subject’s participation in this clinical 
study, the subject’s safety, or the reliability of the study data.  

Protocol: EQ001 -aGVHD -001 
 Page  37 of 87 
Equillium, Inc.  Confidential  5. STUDY TREATMENT(S)  
  
 
 
5.2. Study Drug  
In Part  A, all subjects will receive their cohort assigned dose of EQ001.  In Part B, subjects will 
be randomized  in a blinded fashion  to either EQ001 or placebo using a 2:1 allocation . 
The study drug s are: 
• EQ001 , containing the  active ingredient itolizumab (Bmab 600), a humanized recombinant 
IgG1 mAb that selectively targets the ex tracellular Sc membrane -distal domain  1 of human 
CD6  
• Placebo is a sterile, clear, colorless, preservative -free solution  with the same fo rmulation 
(minus the drug) as EQ001  

Protocol: EQ001 -aGVHD -001 
 Page  39 of 87 
Equillium, Inc.  Confidential   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -[ADDRESS_402296] with any these therapi[INVESTIGATOR_325688], the Medical Monitor should  be informed .  Subjects will be asked to remain in the study  
and complete the remaining visits , but no additional study drug will be administered.  
5.5. Treatment Compliance  
The study drug will be administered open -label in Part A and  in a blinded fashion in Part B  at the 
clinic /facility  by a qualified staff  member .  The  date and start and stop times of the infusion will 
be recorded.  
  
 
 
 
 
 
 
5.7. Enrollment or Randomiza tion and Blinding  
It is the responsibility of the investigator to ensure that subjects are eligible to participate in the 
study prior to enrollment and continue to remain eligible throughout the study.   An interactive 
web response system (IWRS) will be used for the study to ensure study drug inventory , 
accountability  and appropriate cohort allocation and  blinded  treatment assignment.  The site’s 
unblinded Pharmacist or designee will have access to the I WRS  and all treatment assignments.  
5.7.1.  Part  A 
Part A of  the study is open -label.  O nce informed consent has been obtained, all screening 
procedures have been assessed, and study eligibility has been confirmed, subjects will be 
enrolled to receive EQ001 on Study Day 1.  The study Pharmacist or designee will access the 

Protocol: EQ001 -aGVHD -[ADDRESS_402297] resupply . 
5.7.2.  Part  B 
Part B of the study will be randomized, double blinded, and placebo controlled.  Subjects will be 
randomized in a 2:1 ratio to an optimal dose of EQ001 ( as determined in P art A) or placebo.  
Once informed consent has been obtained, all screening procedures have been assessed, and 
study eligibility has been confirmed, subjects will be ra ndomized  to receive either EQ001 or 
placebo on Study Day [ADDRESS_402298] resupply . 
Investigators, site staff, subjects , and the Sponsor an d/or designee  will be blinded to treatment  
assignment .  The unblinded pharmacist or designee  will be instructed not to divulge the 
treatment administered of any subject with the blinded  site personnel, study subject, caregiver , 
and/or Sponsor or  designee . 
The blind should be broken only if knowledge of  the subject’s treatment allocation would 
facilitate specific emergency treatment.  Unblinding procedures are provided in the Pharmacy  
Manual.  The investigator must contact [CONTACT_1052]/or designee prior to unblinding a 
subject’s treatment assignment .  In the event of an emergency when unblinding is necessary and 
the Sponsor and/or designee  could not be contact[INVESTIGATOR_530], the investi gator should contact [CONTACT_63307]/or designee  as soon as possible after the unblinding.  
  
 
 
 
 
 
Upon completion or termination of the study, all unused and partially used (if allowed by 
[CONTACT_3725]/institutional procedure to be retained) investigational  product  must be returned to the 
Sponsor (or designated agent) unless the Sponsor authorizes the study site to destroy 
investigational product . 
If the Sponsor authorizes the study site to destroy investigational product , the investigator is 
responsible to ensure that arrangements are made for proper disposal.  Written authorization 
should be issued by [CONTACT_1034]; procedures for proper disposal should be established according 
to applicable regulations, guidelines, and procedures; and appro priate records of the disposal 
should be documented and forwarded to the Sponsor.  

Protocol: EQ001 -aGVHD -[ADDRESS_402299] , the unblinded study monitor will 
facilitate the return of unused and/or partially used investigational pro duct. 

Protocol: EQ001 -aGVHD -[ADDRESS_402300] ’s medical record and the appropriate electronic case 
report f orm ( eCRF ). 
6.1. Screening and Informed  Consent  
Before subject s commence any study -specific activities or procedures, the Sponsor requires a 
copy of the study site’s written Institutional Review Board (IRB) approval of the protocol, 
informed consent form (ICF), and all other subject  information and/or recruitment mat erial, if 
applicable.  Each subject  (or legally acceptable representative) must sign and date the ICF before 
participating in study -specific activities.  
After the ICF is signed, the subject  enters screening.  Each subject  will be assigned a unique 
subject number at the time of screening .  Subject numbers will be sequential within each study 
site.  If more than one (1) assessment is performed during screening, the initial assessment 
closest to the enrollment date  and time  will be used for e ligibility.   Subjects must have their first 
dose of study drug within 72 hours (3 days) of their first corticosteroid dose , therefore, sites 
should consent and start screening  subjects as soon as aGVHD is suspected . 
This subject number, assigned at the time of screening, will be used to identify the subject 
throughout the study and must be used on all study documentation related to that subject.  The 
subject identification number will  remain constant throughout the en tire study; it must not be 
changed after initial assignment.  Each  study site will maintain a list identifying all subjects by 
[CONTACT_325701].  
After completing the screening period, the subject  will be evaluated by [CONTACT_325702] .  A subject  is considered enrolled when the investigator decide s that all of the 
eligibility criteria are met.  The investigator will document this decision and date  and time  in the 
subject ’s medical record and the eCRF.  Screen failure subject s will be entered into the eCRF.  
Investigators will maintain a screening log of all potential study candidates that includes limited 
information about each candidate, dates, and outcome of screening process (e.g., enrolled into 
study, reason for ineligibility, or withdrawal of consent).  
6.2. Demographics and Medical History  
Demographic data including sex, age, race, and ethnicity will be collected.  
The investigator or designee will collect medical and surgical history that started prior to 
enrollment , including information on the subject ’s concurrent medical conditions.  All findings 
will be recorded on the medical history eCRF.  

Protocol: EQ001 -aGVHD -[ADDRESS_402301]  complaints or changes 
from baseline , including clinical grade of aGVHD at diagnosis and organ involvement at 
diagnosis , infusion -related  reaction s, and examinations for potential hypersens itivity reactions . 
6.4. Vital Signs  
The following vital sign measurements will be performed: systolic and diastolic blood pressure, 
pulse, respi[INVESTIGATOR_1487], and temperature .  On dosing days, v ital signs will be monitored  pre-dose 
and every 30 minutes (± 5 minutes)  
The subject  must be in seated or in a semi -recumbent position in a rested and 
calm state for at least [ADDRESS_402302]  should be the same throughout the study and documented on the vital signs eCRF.  
Height will be measured without shoes at screening.  
Weight without shoes will be obtained at screening.  On dosing days, weight will be collected 
pre-dose.   The weight at screening will be used to calculate all study drug doses unless there has 
been a change in weight by 20% or greater.  An additional subsequent change in dosing will not 
occur unless there is a change in weight of 20% or more from the new weig ht that required the 
dosing change to be made (no longer referencing back to the Screening weight at subsequent 
doses ). 
  
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  46 of 87 
Equillium, Inc.  Confidential    
 
 
 
 
 
 
 
 
 
 
6.7. Biops y Review  
Any relevant tissue biopsy ( eg, gastroin testinal, liver , bone marrow, or skin) , performed per 
standard of care to support the clinical diagnosis and/or management of a subject’s aGVHD at 
any time prior to and during the subject’s enrolment,  should  be collected  and the clinical data 
derived from the biopsy entered into the eCRF.  Biopsies that were performed prior to and during 
screening to confirm the diagnosis of aGVHD  should be recorded.  
6.8. Minimal Residual Disease (MRD)  
Assessments of MRD should be captured if they were done anytime f rom the time of the HSCT 
through baseline (Day 1).  
6.9. Chronic GVHD (cGVHD)  
An assessment of cGVHD will be performed during the long -term follow -up visits.  
6.10. 12-Lead Electrocardiography  
The subject  must be in a seated, semi -recumbent, or supi[INVESTIGATOR_33197] a res ted and calm state for 
at least 10 minutes before ECG assessment is conducted.  Each 12 -lead ECG should be 
performed prior to blood draws, dosing (if applicable , except f or Baseline  post-dose ECG ), or 
other invasive procedures.  
In Part  A, a single  ECG will  be recorded using the site’s standard ECG equipment.  The 
investigator or designated study site physician will review, sign , and date all ECGs.   The original 
ECGs will be retained with the subject ’s source documents.  At the request of the Sponsor, a 
copy of the original ECG will be made available to the Sponsor .  Each ECG should  capture QRS, 
QT, QTc, RR, and PR intervals and be documented on the ECG eCRF.  
In Part  B, ECG s in triplicate  taken over 5 minutes will be recorded using the ECG equi pment  
provided and  transmitted to a central ECG reader .  The ECG results will be assessed by [CONTACT_11136], 
independent, central review  to evaluate changes in ECG intervals and morphology as compared 

Protocol: EQ001 -aGVHD -[ADDRESS_402303]’s source documents.  
Any clinically significant abnormal ECG findings will be recorded as AEs.  
6.11. Clinical Laboratory Tests  
6.11.1.  Local Laboratory Parameters  
Blood samples will be collected  
, Protocol Section  [ADDRESS_402304] will be conducted at the 
local clinic/ facility.  Samples will be collected pre -dose on study dosing days.  Repeat laboratory 
testing is not required if a test was already performed within the specified time window for 
collection.   Samples may be analyzed for the tests outlined in this protocol and for any additional 
tests necessary to ensure subject  safety.  These may include, but are not limited to, investigation 
of unexpected results .  Subject s will be in a seated, semi -recumben t, or supi[INVESTIGATOR_325689].   

Protocol: EQ001 -aGVHD -001 
 Page  48 of 87 
Equillium, Inc.  Confidential  6.11.2.  Central Laboratory Parameters  
Blood, skin biopsy , and stool samples will be collected  
 Protocol Section  8 and below from screening through the follow -
up visits and submitted to the central laborator ies for analysis.   
 
 
[IP_ADDRESS].  Pharmacokinetic   
In Part A only, serum will be assayed for EQ001 concentrations using a validated assay.  PK 
samples will be collected at time points specified below .  Based on emerging PK data, the actual 
collection times may change after discussion between the investigator and Sponsor.    
 
  
 
  
  
  
  
  
  
  
  
 
 
[IP_ADDRESS].  Anti -Drug Antibody  (ADA)  and Neutralizing ADA  (NAB)  
Serum samples will be obtained for detection of ADA against EQ001 as outlined below  and if 
required  a neutralizing ADA assay will be run on the same sample.  Samples will be batched and 
run at the end of Part A and at the end of  Part B .   
 
 
  
  
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  49 of 87 
Equillium, Inc.  Confidential    
 
 
  
   
  
  
  
   
  
 
  
  
 
  
 
 
  
  
  
 
  
 
  
  
 
  
  
 
  
 
 
  
  
  
 
 
  
 
 

Protocol: EQ001 -aGVHD -001 
 Page  50 of 87 
Equillium, Inc.  Confidential    
   
 
 
 
  
 
 
 
 
 
   
 
  
  
  
  
  
  
 
 
 
  
  
 
  
  
  
 
  
  
 
  
  
  
  
  
 
   
  
  
  
   
 
  
  
  
  
 
 
 
  
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -[ADDRESS_402305]’s early termination or termination of the study  (see Section  8.12 or Section  8.15, as 
appropriate) . If consent has not been withdr awn, AEs will continue  to be collected as described 
in Section 7. 
A termination case report form ( CRF ) page will be com pleted for every subject enrolled, whether 
or not the subject completed the study.  The reason for any early discontinuation from the stud y 
should be indicated on this form.  Separate CRF entries will document whether each subject 
completed all doses of study drug, or if not, the reason a subject terminated study drug early.  
The investigator will discuss with the subject/subject’s parent(s) or legally acceptable 
representative(s) the most appropriate way to withdraw to ensure the subject’s health.  Should a 
subject (or a legally acceptable representative) request or decide to withdraw consent, all efforts 
will be made to complete and report t he observations as thoroughly as possible up to the date of 
withdrawal.  

Protocol: EQ001 -aGVHD -001 
 Page  52 of 87 
Equillium, Inc.  Confidential  7. ADVERSE EVENTS  
An AE is any unfavorable and unintended sign (including an abnormal laboratory  finding), 
symptom, or disease  or any worsening of a pre -existing condition  temporally associated with the 
use of a  study drug , whether or not related to the study drug .  AEs that occur after the first dose 
of EQ001 or during the study treatment and safety follow -up periods  will be documented  on the 
AE eCRF.  The investigator will assess the AE severity and relationship of the AE to study  drug.  
The investigator will treat the subject  as medically required.  
Laboratory values that are outside the laboratory reference range sh ould be reported as AEs only 
if considered clinically significant by [CONTACT_093] . 
From the time of obtaining informed consent through the first administration of study drug , all 
SAEs and nonserious AEs related to protocol  mandated  procedures will be r ecorded on the 
SAE/AE eCRF.  All other untoward medical occurrences observed during screening, including 
exacerbation or changes in medical history, will be captured on the medical history eCRF.  
Details on recording and reporting AEs are provided below .  
AEs will be collected  through Study Day 169 for subjects who complete study drug through 
Day 57. AEs will be collected through Study Day 85 for subjects who discontinue study drug  
early . Recent hospi[INVESTIGATOR_325690], if applicable, will be recorded at the Day 253 and 337 
visits.  
The investigator’s clinical judgment should be used to determine whether a subject  is to be 
withdrawn due to an AE.  In the event the subject  requests to withd raw from study -related 
treatment , the subject  should be asked to return for all remaining study visits through Study Day 
169.  In the event a subject  is withdrawn from study, an early -termination visit should be 
completed.  
All subjects experiencing AEs  while on st udy drug , including clinically significant abnormal 
laboratory values, whether  or not associated with use of the study drug, must be monitored until 
the condition returns to normal, returns to the subject ’s baseline, until the investigator determines 
the AE has reached a stable outcome and is no longer clinically significant, or the  subject  is 
considered lost to follow up . 
If consent has not been withdrawn, all deaths should be reported  through Study Day 337 , even if 
study drug has been discontinued.  
7.1. Severity  
All AEs, both serious and non -serious, will be assessed for severity using the Common 
Terminology Criteria for Adverse Events ( CTCAE ) v5.0.  The CTCAE scale includes unique 
clinical descriptions of AEs that are categorized by [CONTACT_248953]/or pathophysiology.  Reference 
the following website: 
https://ctep.cancer.gov/protocolDevelop ment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_8.5x11.pdf  
The CTCAE scale displays Grades 1 through 5 with unique clinical descriptions of severity for 
each AE (including abnormal laboratory values) based on this general guideline provided in t he 
CTCAE scale.  For any AEs not covered by [CONTACT_325703].  

Protocol: EQ001 -aGVHD -001 
 Page  53 of 87 
Equillium, Inc.  Confidential  • Grade 1 (Mild) AE: minor; no specific medical intervention; marginal clinical relevance  
• Grade 2 (Moderate) AE: minimal intervention; local intervention;  noninvasive intervention  
• Grade 3 (Severe) AE: significant symptoms requiring hospi[INVESTIGATOR_84006]  
• Grade 4 (Life -threatening or disabling) AE: Complicated by [CONTACT_9420], life -threatening 
complications; need for intensive care or emergent inv asive procedure  
• Grade 5 Fatal AE  
7.2. Relationship  
The investigator or qualified sub-investigator is responsible for assessing the relationship to 
study drug using clinical judgment and the following considerations:  
• Related: The AE is definitely related to study medication administration.  
• Probably Related: There is a high degree of certainty that the AE is related to study 
medication administration.  
• Possibly Related: The AE could be related either to study medication administration or to 
concurrent disease/m edication.  
• Unlikely Related: There is a high degree of certainty that the AE is NOT related to study 
medication administration.  
• Not Related:  The AE is clearly due to other causes (e.g. , concurrent medication, underlying 
disease, etc. )  
The relationship to study -related procedures (e .g., invasive procedures such as venipuncture) 
should be assessed using the following considerations:  
• Related: The AE is definitely related to study -related procedures.  
• Probably Related: There is a high degree of certainty that the AE is related study -related 
procedures.  
• Possibly Related: The AE could be related either to study -related procedures or to concurrent 
disease/medication.  
• Unlikely Related: There is a high degree of certainty that the AE is NOT related to  study -
related procedures.  
• Not Related:  The AE is clearly due to other causes (e.g. , concurrent medication, underlying 
disease, etc.). In making a causality assessment of an AE, consideration should be made as to 
whether or not the event is expected to occu r due to the underlying disease based on the 
investigator’s prior clinical experience in the ma nagement of aGVHD (see Section  7.5.1 ). 
7.3. Clinical Laboratory Adverse Events  
The investigator is responsible for reviewing the results of all laboratory tests as they become 
available and determining whether an abnormal value in an  individual study subject  represents a 
clinically significant change from the subject ’s baseline value(s).  The investigator may repeat 
the laboratory test or request additional tests to verify the results of the original laboratory tests.  
In general, abno rmal laboratory findings without clinical significance (based on the investigator's 
judgment) are not to be recorded as AEs.  However, laboratory value changes that require 

Protocol: EQ001 -aGVHD -001 
 Page  54 of 87 
Equillium, Inc.  Confidential  treatment or adjustment in current therapy are considered AEs.  Where applicable, c linical 
sequelae (not the laboratory abnormality) are to be recorded as the AE.  
7.4. Serious Adverse Events  
An SAE is defined by [CONTACT_325704]:  
• death,  
• life-threatening AE  (Note: A life -threatening AE is one that, in the view of the investigator, 
places the subject at immediate risk of death from the reaction as it occurred) , 
• hospi[INVESTIGATOR_1081],  
• a persistent or significant disability /incapacity, or  
• a congenital anomaly/birth defect.  
Important medical events that may not result in death, be life threatening, or require hospi[INVESTIGATOR_325691], based upon appropriate medical judgment, they may jeopardize  
the subjec t and may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition.   Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or c onvulsions 
that do not result in subject  hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
An unexpected AE is any event for which the specificity or severity is not consistent with the AE 
profile in the current EQ001  Investigator’s  Brochure . 
All SAEs, regardless of caus e(s) or relationship to study drug, must be reported within 24 hours 
to the study Sponsor and/ or designee.  
7.5. Reporting Adverse  Events  
7.5.1.  Reporting Procedures for Non -Serious Adverse Events  
The investigator is responsible for ensuring that all AEs observed by [CONTACT_325705].  
The investigator will assign the following AE attributes:  
• AE diagnosis or syndrome(s), if known (if not known, sign s or symptoms)  
• Dates of onset and resolution (if resolved)  
• Severity  
• Relatedness to study drug or study -related procedures  
• Action taken  
• Outcome  
Follow -up of non -serious AEs will continue through the last day on the study and/o r until a 
definitive outcome (e .g., resolved, resolved with sequelae, lost to follow -up) is achieved.  

Protocol: EQ001 -aGVHD -[ADDRESS_402306]  is withdrawn from the study because of a non -serious AE, the Sponsor and/or 
designee must be notified by e -mail or phone within [ADDRESS_402307]  are promptly assessed and reported  to the Sponsor and/or designee .  The investigator  
must assess whether the SAE is rel ated to study drug or any study -related procedure.  
The procedures for reporting SAEs are as follows:  
• Record the SAE on the AE eCRF and complete the “Serious Adverse Event Report” form.  
• Within 24  hours of the investigator’s knowledge of the event, e -mail, fax and/or enter via the 
electronic CRF the SAE Report form to the attention of the Sponsor  and/or designee .  
Additional contact [CONTACT_325706]/SAE reporting instructions will be provided in the Study 
Manual . 
• For fatal or life -threatening events, also e -mail and/or fax copi[INVESTIGATOR_3103], 
autopsy reports, and other documents, when requested and applicable.  Transmission of such 
documents should occur with personal subject  details de -identified, wit hout losing the 
traceability of a document to the subject  identifiers.   Transmission of the initial report of the 
event should not be delayed in order to include these additional documents.  
• The Sponsor or /or designee may request additional information from  the investigator to 
ensure the timely completion of accurate safety reports.  
The investigator must take all therapeutic measures necessary for resolution of the SAE.  Any 
medications or therapi[INVESTIGATOR_325692].  
Follow -up of SAEs will continue through the last day on the study and/or until a definitive 
outcome (e .g., resolved, resolved with sequelae, lost to follow -up, fatal) is achieve d. 
While pregnancy is not considered an AE, all cases of fetal drug exposure via a maternal parent 
as study subject  or pregnancy of a partner of a male study subject  will be reported immediately 
to the Sponsor or its designee.  Information related to the p regnancy must be documented on a 
“Pregnancy Confirmation and Outcome” form, provided by [CONTACT_4885], and the 
pregnancy should be followed until a definitive outcome has been determined.  
Some SAEs will qualify for reporting to the FDA as app licable via the MedWatch reporting 
system in accordance with FDA and other applicable regulations.  The Sponsor or its designee 
will report SAEs as required to regulatory authorities, investigators in compliance with all 
reporting requirements according to  local regulations and Good Clinical Practice (GCP).  
The investigator will notify the appropriate IRB of SAEs occurring at the study site and other AE 
reports received from the Sponsor, in accordance with local procedures and statutes.  The 
investigator or designee at each study site is responsible for submitting Investigational New 

Protocol: EQ001 -aGVHD -001 
 Page  56 of 87 
Equillium, Inc.  Confidential  Drug  (IND) safety reports (initial and follow -up) and other safety information (e .g., revised 
Investigator’s Brochure) to the IRB and for retaining a copy in the study files.  
  
 
 
 
 
 
  
   
   
   
    
 
  
 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  57 of 87 
Equillium, Inc.  Confidential  8. STUDY ACTIVITIES  
Please refer to the Appendices, Section  12, for additional details.    
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  58 of 87 
Equillium, Inc.  Confidential   EQ001 T  cell stimulation  
  
  
  
  
  
  
  
  
  
 
  
 
  
 
   
   
  
 
  
  
  
   
  
  
 
  
  
  
  
  
  
   
  
  
  
  
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  59 of 87 
Equillium, Inc.  Confidential    
  
  
  
  
   
   
  
   
  
  
  
  
  
  
  
  
 tments  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  

Protocol: EQ001 -aGVHD -001 
 Page  60 of 87 
Equillium, Inc.  Confidential   
  
 
  
 
  
  
  
  
  
  
   
  
  
   
  
   
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  61 of 87 
Equillium, Inc.  Confidential   
  
 
  
 
   
  
 
  
  
 
  
  
  
  
  
  
  
  
   
   
 
  
 
  
 
  
 
  
  
 
  
  
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  62 of 87 
Equillium, Inc.  Confidential    
   
  
  
  
  
  
  
  
  
  
  
  
  
   
  
  
  
 
  
 
  
 
  
   
  
  
  
  
   
  
 
  
  
 
 
 
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  63 of 87 
Equillium, Inc.  Confidential    
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
  
  
  
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  64 of 87 
Equillium, Inc.  Confidential    
 
 
 
   
  
  
  
  
  
  
   
  
  
  
  
  
  
   
  
  
  
  
   
  
  
  
  
  
  
  

Protocol: EQ001 -aGVHD -[ADDRESS_402308] should complete an unscheduled visit 
that includes disease assessments and grading.  
   
 
  
  
  
 
  
  
   
  
  
  
  
  
    
  
  
 
  
 
 
  
  
  

Protocol: EQ001 -aGVHD -001 
 Page  66 of 87 
Equillium, Inc.  Confidential  9. PLANNED STATISTICAL  METHODS  
A detailed description of data analysis and statistical methods to be used will be outlined 
separately in a Statistical Ana lysis Plan (SAP).  
9.1. General Considerations  
Data will be summarized using descriptive statistics (n, mean, median, standard deviation, 
minimum, maximum) for continuous variables and frequencies and percentages for discrete 
variables.  All data summaries will be displayed by [CONTACT_325707] P art A and by [CONTACT_7273] B.  A total column will also be included.  By -subject listings of the data will also be 
provided.  All data summaries and listings will be produced using the SAS® software Version  9.[ADDRESS_402309] one (1) measurable post -EQ001exposure 
concentration  will be included in the PK analysis population . 
  
 
 

Protocol: EQ001 -aGVHD -001 
 Page  68 of 87 
Equillium, Inc.  Confidential  Clinical laboratory data will be summarized descriptively, these summaries will include observed 
values at collection timepoints and change from baseline.  All laboratory parameters that can be 
graded using the CTCAE will be graded.   
 
  
  
 
 
  
 
. 
9.9. Efficacy Analyses  
  
All efficacy data summaries for  Part A will use the safety population , whereas Part B will use the 
efficacy population for P art B.  Clinical activity will be assessed by [CONTACT_222000] : 
aGVHD Organ Stages and Overall Clinical Grading  and aGVHD -AI.  Corticosteroid and 
immunosuppressive agent usage  will be compared between groups .  Overall mortality  and 
nonrelapse -mortality  at 12 months, overall response rate (proportion of subjects with a best 
response of PR or better during the 12-month assessment period  compared to last pre -dose 
assessment ) and K aplan -Meier estimates of progression -free survival will also be calculated.  In 
general, changes from baseline in numeric variables will be compared between the two  groups 
using an analysis of covariance model with baseline value as a covariate.  Proportio ns will be 
compared between the groups using the Fisher’s Exact  test.  Time to event data will be compared 
using the log-rank test . 
  
 
 
 

Protocol: EQ001 -aGVHD -[ADDRESS_402310].  The investigator is responsible 
for ensuring that the investigation is conducted according to the signed Investigator Agreement 
(FDA  Form 1572), the approved protocol, and applicable regulations for protecting the rights, 
safety, and welfare of study subject  under the investigator's care.   The investigator is additionally 
responsible for the control of investigational product and for p roviding accurate and verifiable 
data to the Sponsor.  
The investigator must obtain the Informed Consent and HIPAA authorization of each subject  
before participation in the study.  The investigator must assure initial and continuing review of 
the study by a n IRB that complies with applicable national and local regulations.  
The investigator will maintain minutes of meetings with study staff and document training of 
research study personnel for conduct of the study, including qualifications, experience, and s tudy 
role. 
The investigator will be given a copy of the most current version of the  EQ001 Investigator’s 
Brochure  and appropriate study process manuals and plans.  The investigator is obligated to 
become familiar with all sections of these documents prior to initiation of the study.  
Other investigator responsibilities relative to the IRB include the following:  
• Submit to the IRB for review any advertisements that will be used to recruit subject s 
• Submit all protocol amendments, revisions of th e Investigator’s Brochure, or revisions of the 
Informed Consent to the IRB for review  
• If Sponsor notifies the investigator about SAE s reported in other studies associated with this 
investigational product, report that information to the IRB  
• Provide the IRB  with any other information it requests before or during the conduct of the 
study  
• Report to the IRB all adverse drug reactions that are serious, unexpected, and related to 
investigational product  
• Maintain a file of study -related information  
• Update the IRB on a minimum of a yearly basis  
10.2. Institutional Review Board (IRB) Approval  
Before initiation of the study at a study site, the protocol, including the final version of the ICF, 
the subject  information sheet (if applicable), and any other relevant study documentation will be 
submitted to the appropriate IRB.  In addition, the IRB must approve all advertising used to 
recruit subject s for the study.  Written approval of the study documentation, including any 
proposed postings or advertising, must be obtained and sent to the Sponsor or its designee before 
the study site can be initiat ed or the study drug can be released to the investigator .  

Protocol: EQ001 -aGVHD -[ADDRESS_402311] s, and/or other procedures in accordance with local 
requirements .  The protocol must be re -approved by [CONTACT_325708], in 
accordance with applicable law.  The investigator must send a copy of the approval letter from 
the IRB to the Sponsor or its designee.  
The investigator will report promptly to th e IRB and the Sponsor any new information that may 
adversely affect the health or safety of past or current subject s or the conduct of the study, 
including deviations from the protocol or reports of any reportable SAEs, during and for two (2) 
years after c ompletion of the study.  
The investigator should submit written reports of clinical study status to their IRB annually or 
more frequently if required.  A final study notification will also be forwarded to the IRB after the 
study is completed or in the even t of premature termination of the study in accordance with the 
applicable regulations.   After completion of the study, the investigator will provide the IRB with 
a report of the outcome of the study.  Copi[INVESTIGATOR_325693].  Copi[INVESTIGATOR_281921] (including termination) should be provided 
to the Sponsor.  
10.3. Ethical Conduct of the Study  
This study will be conducted in compliance with the protocol; GCP guidelines, including 
International Council  for Harmoni sation  (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use Guidelines (ICH E6); and FDA regulatory requirements.  In 
addition, the study will be conducted in compliance with any and all current laws, require ments, 
regulations (including, but not limited to, HIPAA) of local, state, federal and foreign authorities 
and agencies having jurisdiction over the subject  matter and performance of, and the study 
(referred to herein as “applicable law”).  
Investigators an d all sub-investigators will comply with 21 Code of Federal Regulations (CFR), 
Part 54, [ADDRESS_402312] be provided prior to the investigator’s (and any sub-investigator’s ) 
participation in the study.  The investigator and sub-investigator (s) will notify the Sponsor or its 
designee of any change in reportable interests  during the study and for [ADDRESS_402313] comply 
with the ICH GCP Guidelines, FDA requirements, and local regulatory requirements.  

Protocol: EQ001 -aGVHD -[ADDRESS_402314] be obtained and documented 
prior to initiation of any procedures that are performed solely for the purpose of determining 
eligibility for research, including withdrawal from current medication(s).  The informed consent 
process should take place under conditions where the subject has adequate time to consider the 
risks and benefits associated with his/her participation in the study.  The investigator or qualified 
designee must explain to each subject or legally authorized representative the aims, methods, 
reasonably anticipated benefits, and potential hazards of the study.  
Once appropriate essential information has been provided and fully explained in layman’s 
language to the subject by [CONTACT_20616] r (or a qualified designee), the approved ICF will be 
signed and dated by [CONTACT_123254] ( investigator or designee), 
as well as by [CONTACT_78629].  The subject will receive a copy of the signed 
ICF; the original will be retained in the study files.  The investigator must document the consent 
interview and place the record in the study files.  The investigator shall also maintain a log of all 
subjects who sign the ICF and indicate if the subject was e nrolled into the study or reason for 
non-enrollment.  
10.5. Confidentiality  
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties.  Only subject initials, date of birth,  another 
unique identifier (as allowed by [CONTACT_1769]) and an identification code will be recorded on any 
form or biological sample submitted to the Sponsor, IRB, or laboratory.  Laboratory specimens 
must be labeled in such a way as to protect subject identi ty while allowing the results to be 
recorded to the proper subject.  Refer to specific laboratory instructions (or in accordance with 
local regulations ).  NOTE: The investigator must keep a screening log showing codes, names, 
and addresses for all subjects  screened and for all subjects enrolled in the study .  Subject data 
will be processed in accordance with all applicable regulations.  (Some studies may require 
double -coding of samples; insert language as appropriate. ) 
The investigator agrees that all info rmation received from the Sponsor , including but not limited 
to the Investigator’s Brochure , this protocol, CRF/eCRF, the study drug, and any other study 
information, remain the sole and exclusive property of the Sponsor  during the conduct of the 
study and  thereafter.  This information is not to be disclosed to any third party (except employees 
or agents directly involved in the conduct of the study or as required by [CONTACT_2371]) without prior 
written consent from the Sponsor .  The investigator further agrees to ta ke all reasonable 
precautions to prevent the disclosure by [CONTACT_191856].   In compliance with applicable law and/or ICH GCP 
Guidelines, the investigator will permit the Sponso r’s representatives and, when necessary, 
representatives of the FDA or other regulatory authorities’  direct access to any medical records 
relevant to the study for verification of study -related procedures and data.  Direct access includes 
examining, analyzing, verifying, and reproducing any records and reports that are important to 
the evaluation of the study.  

Protocol: EQ001 -aGVHD -[ADDRESS_402315] (i.e., specific permission granted by [CONTACT_325709] a covered entity for the use or disclosure of an individual's protected health information).  The 
investigator and institution must obtai n such waiver/authorization in writing from the subject or 
legally authorized representative.  Valid authorization must meet the implementation 
specifications under the applicable privacy laws.  Authorization may be combined in the ICF 
(approved by [CONTACT_1201] ), or it may be a separate document (approved by [CONTACT_1201]) or provided by 
[CONTACT_76617] (without IRB approval).  
10.6. Study Initiation  
Before the study drug can be shipped to the study site and before the study can begin, the 
following documents mus t be submitted and received by [CONTACT_1034]:  
• Original US FDA Form 1572  signed by [CONTACT_093]  
• Documentation of the IRB approval of the protocol and Informed Consent  
• A copy of the IRB -approved Informed Consent and HIPAA authorization that will be used  
• Copy of current curriculum vitae and medical licenses of the investigator  
• A membership list of the IRB  
• Investigator’s financial disclosure form  
The Sponsor will notify the site when the study can begin.  
10.7. Case Report  Forms and Study Records  
The investigator will comply with the requirements for all assessments and data collection for 
each subject, as specified in the protocol.  
During each subject’s visit to the clinic, the investigator or qualified designee will record 
progress notes in the subject’s medical record to document all significant observations.  At a 
minimum, these notes will contain the following:  
• Documentation of the informed consent process, including any revised consents . 
• The date of the visit and the corresponding visit or day in the study schedule . 
• General subject status remarks, including any significant medical findings.  The severity, 
frequency, and duration of any AEs and the investigator's assessment of relationship  to study 
drug must also be recorded . 
• Any changes in concomitant medications . 
• A general reference to the procedures completed . 
• The signature (or initials) and date of all clinicians who made an entry in the progress notes . 

Protocol: EQ001 -aGVHD -[ADDRESS_402316] Operating Procedures.  
Clinical data (including AEs, concomitant medications, and clinical laboratory data) will be 
entered into a database.  The creation and validation of the database, data entry, validation, and 
verification will be performed according to [ADDRESS_402317] copi[INVESTIGATOR_325694].  
By [CONTACT_12570], the investigator grants permission to personnel from the Sponsor, its 
representatives, and appropriate regulatory authorities for on -site monitoring and review of all 
appropriate study documentation, as well as on -site review of the procedures employed in data 
collection, where c linically appropriate.  
10.10.  Study or Study Site Termination  
The Sponsor may suspend or stop the study at all centers or at specific study centers due to (but 
not limited to) the discovery of an unexpected, serious, or unacceptable risk to the subjects 
enrolled in the study, a decision on the part of the Sponsor to suspend or discontinue 
development of the product, failure of the investigator to enroll subjects into the study at an 
acceptable rate, failure of the investigator to comply with regulatory authority o r ICH 
Guidelines, or submission of knowingly false information . 

Protocol: EQ001 -aGVHD -001 
 Page  74 of 87 
Equillium, Inc.  Confidential    
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10.13.  Quality Assurance  
Authorized representatives of the Sponsor, a regulatory authority, or IRB may visit the study site 
to perform audits or inspections, including source data verification.  The purpose of any such 
audit or inspection is to systematically and independently exa mine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, ICH GCP guidelines, and any other 
applicable regulatory requirements.  

Protocol: EQ001 -aGVHD -[ADDRESS_402318] retain the essential documents for as long as 
needed to comply with regulatory guidelines and Sponsor requirements.  The investigator will 
notify the Sponsor pr ior to moving or destroying any of the study documents.  It is the 
responsibility of the Sponsor to inform the investigator /institution as to when these documents no 
longer need to be retained.  The investigator should take measures to prevent any accidental or 
premature destruction of these documents.  
10.15.  Study Report and Publication s 
A clinical study report (CSR) will be prepared and provide d to the regulatory agency(ies).  The 
Sponsor  will ensure that the report meets the standards set out in the ICH Guideline for Structure 
and Content of Clinical Study Reports (ICH E3).  Note that an abbreviated report may be 
prepared in certain cases.  
Investigators in this study may communicate, orally present, or publish in scientific journals or 
other scholarly media only after written consent has been obtained from the Sponsor . 
The investigator will submit to the Sponsor  any proposed publication or prese ntation along with 
the respective scientific journal or presentation forum at least 60 days before submission of the 
publication or presentation .  
No such communication, presentation, or publication will include the Sponsor ’s confidential 
information (see Section  10.5). 
The investigator will comply with the Sponsor ’s request to delete references to its confidential 
information (other than the study results) in any paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary . 

Protocol: EQ001 -aGVHD -001 
 Page  76 of 87 
Equillium, Inc.  Confidential    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  77 of 87 
Equillium, Inc.  Confidential   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  78 of 87 
Equillium, Inc.  Confidential   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  79 of 87 
Equillium, Inc.  Confidential   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol: EQ001 -aGVHD -001 
 Page  80 of 87 
Equillium, Inc.  Confidential    
  

Protocol: EQ001 -aGVHD -001 
 Page  81 of 87 
Equillium, Inc.  Confidential  

Protocol: EQ001 -aGVHD -001 
 Page  82 of 87 
Equillium, Inc.  Confidential  

Protocol: EQ001 -aGVHD -001 
 Page  83 of 87 
Equillium, Inc.  Confidential  

Protocol: EQ001 -aGVHD -001 
  of 87 
Equillium, Inc.  Confidential    

Protocol: EQ001 -aGVHD -001 
 Page  85 of 87 
Equillium, Inc.  Confidential  

Protocol: EQ001 -aGVHD -001 
 Page  86 of 87 
Equillium, Inc.  Confidential  

Protocol: EQ001 -aGVHD -001 
 Page  87 of 87 
Equillium, Inc.  Confidential  
